GoodRx Restates Q1/Q2 2026 Revenue, Flags Material Weaknesses
GDRX has more than doubled off its 52-week low of $1.77.
Summary
GoodRx will restate Q1 and Q2 2026 results after understating Pharma Direct revenue, adding $29.8M to six-month revenue, and expects to report material weaknesses in internal controls.
Key Events · Legal and Risk Events · GDRX
-
Q1/Q2 2026 Financials No Longer Reliable
The Audit and Risk Committee concluded on October 27, 2026 that condensed consolidated financial statements for the quarters ended March 31 and June 30, 2026 should not be relied upon due to understated Pharma Direct revenue.
-
Restatement Adds $29.8M to Six-Month Revenue
Total revenue for the six months ended June 30, 2026 rises from $394.4M as reported to $424.2M as restated; Q2 Pharma Direct revenue goes from $61.6M to $83.9M and Q2 net income from $8.5M to $19.6M.
-
Material Weaknesses Expected
The company expects to report that one or more material weaknesses in internal control over financial reporting existed as of the end of each affected period, and is assessing disclosure controls.
-
Amended 10-Qs Pending
Restatement figures are preliminary; GoodRx intends to file amended Forms 10-Q for the affected periods as soon as practicable.
Analysis · GDRX · Technology
GoodRx's audit committee has concluded that its Q1 and Q2 2026 financials can no longer be relied upon because Pharma Direct revenue was understated — the correction adds $29.8M of revenue across the six months ended June 30, 2026. The company also expects to report one or more material weaknesses in internal control over financial reporting for those periods. Restatements plus control failures undermine confidence in reported numbers and invite scrutiny of the revenue-recognition process, and the company still has to file amended 10-Qs. Notably, the correction is favorable to reported revenue and net income, but the credibility hit and the open review are what matter here.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDRX was trading at $3.55 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.77 to $3.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.